These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32907476)

  • 1. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 2. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
    Vidyasagar N; Bunting SR; Arora VM; Ari M
    JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Release Buprenorphine Receives FDA Green Light.
    Harris E
    JAMA; 2023 Jun; 329(24):2119. PubMed ID: 37285164
    [No Abstract]   [Full Text] [Related]  

  • 4. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 6. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 7. Buprenorphine for Opioid Use Disorder-An Essential Medical Treatment.
    Weimer MB; Morford KL
    JAMA Intern Med; 2024 Oct; 184(10):1248-1249. PubMed ID: 39186298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 9. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 10. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 11. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
    Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
    JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing engagement between legislators and nursing to increase buprenorphine access.
    Finnell DS; Schimmels J; Tierney M
    Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
    Lapeyre-Mestre M
    Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility.
    Weeks A; Cogger S; Clark N
    Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545
    [No Abstract]   [Full Text] [Related]  

  • 15. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 17. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 18. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 19. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.